Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.79 USD | -4.96% | -16.98% | +28.07% |
Mar. 21 | Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC | CI |
Mar. 19 | Fate Therapeutics Prices $100 Million Offering, Private Placement | MT |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Dividend / Share (DPS) - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- FATE Stock
- Revisions Fate Therapeutics, Inc.